Swedish Orphan Biovitrum's Hemophilia A Therapy Receives European Commission Orphan Drug Designation
Treatment of severe hemophilia A requires frequent infusions, creating a significant burden for individuals with the condition. The rFVIIIFc molecule, which is based on Biogen Idec's novel and proprietary monomeric Fc-fusion technology, is being investigated for the potential to prolong protection from bleeding and reduce the frequency of injections for both prophylaxis and on-demand therapy in hemophilia A.
"The orphan drug designation is very valuable for our promising and high-opportunity rFVIIIFc project as it allows European Medicine Agency fee reduction, protocol scientific advice, and gives market exclusivity once the product is approved and receives orphan status. This will help us in our efforts to bring this innovative rFVIIIFc product to hemophilia patients," said Peter Edman, Ph.D., Chief Scientific Officer of Swedish Orphan Biovitrum.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.